Nonapeptide neuropeptide – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

DSIP (delta sleep-inducing peptide) is a 9-amino-acid neuropeptide that consolidates deep slow-wave sleep. Used historically in research as a sleep aid, particularly for opioid withdrawal. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

Endogenous sleep nonapeptide with uncharacterized mechanism and five decades of modest, variable results

Look, DSIP has a great origin story. The Schoenenberger-Monnier group pulls a nonapeptide out of rabbit cerebral venous blood during slow-wave sleep in 1977, names it Delta Sleep Inducing Peptide, and you’d think the field was off to the races. Forty-seven years later we’re still arguing about what receptor it binds, what signaling it drives, and whether the sleep effect is real or an artifact of model selection. Thats not a good sign for a compound this old.

The mechanism problem is the core issue here. Most peptides that have stayed in the literature this long have at least earned a defined receptor or downstream target. DSIP hasn’t. Binding sites are unconfirmed, downstream effectors are hypothesized rather than demonstrated, and the endogenous plasma and CSF concentrations oscillate with circadian rhythm in ways that suggest a role in sleep architecture but don’t specify it. We’d normally credit a compound for having a novel, incompletely understood mechanism when the incompleteness is recent. Here it’s not recent; it’s just unresolved after decades of work, which is a different thing entirely.

The clinical record is thin and honest about its thinness. The alcohol and opioid withdrawal studies from the 1980s and 90s showed some signal, but the designs were small, controls were inconsistent, and follow-up replication never materialized in a serious way. The chronic pain work is similarly suggestive without being convincing. Even the sleep effect itself, which is literally in the name, comes out as modest and variable across independent labs. When your flagship claim can’t reliably replicate over five decades, you have to question whether the effect is real at the doses studied or real only in specific species or preparation conditions.

Where we do give DSIP some credit is as a target for investigators specifically working on endogenous neuropeptide contributions to sleep regulation and stress response. It’s one of the few characterized endogenous peptides with proposed roles across sleep, circadian gating, and HPA-axis modulation, even if none of those roles are well-defined mechanistically. If your lab is trying to map what the brain does to signal sleep onset at the peptide level, DSIP is a legitimate object of study. It’s just not a tool you’d trust as a probe for a defined pathway, because the pathway isn’t defined.

Honestly, DSIP is a compound the field has never quite given up on and never quite validated. The score reflects that honestly.

Novelty: 30
Mechanism promise: 22
In-category differentiation: 22
Evidence quality: 38
Translational signal: 30
Research bench value: 40

Rationale DSIP scores low primarily because its mechanism remains undefined after 47 years of study, its flagship effect is conceded to be modest and variable even by its proponents, and it has been outcompeted in every clinical indication it touched. The bench value credit is real but limited: as a probe for endogenous sleep-regulatory neuropeptide signaling it’s interesting in principle, but you can’t use an uncharacterized binding site as a reliable experimental handle.

Nonapeptide neuropeptide

An endogenous nonapeptide isolated from rabbit cerebral venous blood with sleep-promoting and stress-modulating activity.

Abstract

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; CAS 62568-57-4; molecular weight 848.81) is a nonapeptide isolated in 1977 by the Schoenenberger-Monnier group from rabbit cerebral venous blood collected during electrically induced slow-wave sleep. The compound is endogenously present in mammalian brain and plasma, with proposed roles in sleep regulation, stress response, and circadian rhythm modulation. Despite the name, the sleep-promoting effect is modest and variable across studies. Mechanism is incompletely characterized; binding sites and downstream signaling have not been definitively established. The compound has been studied in alcohol withdrawal, opioid withdrawal, and chronic pain. Administered subcutaneously or intranasally; oral bioavailability is poor. Research-grade doses are typically 100 to 500 micrograms per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-123Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Nonapeptide neuropeptide

DSIP (Delta Sleep Inducing Peptide)

Abstract

Read the full monograph